文献速递乳腺癌

18F-氟雌二醇(18F-FES)CT/PET 对 ER+/HER2 阴性转移性乳腺癌内分泌治疗反应性的早期预测:一项先导研究

Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET.
PubMed 文献 · Ann Oncol · 2024-02-28

ET-FES 先导研究纳入 147 例 ER+/HER2 阴性转移性乳腺癌患者,基线行 18F-FES PET/CT。SUV≥2 者 117 例接受单药内分泌治疗;SUV<2 者 30 例随机接受内分泌治疗(A 组)或化疗(B 组)。中位随访 62.4 个月,SUV<2 者 A 组中位 PFS 12.4 个月 vs B 组 23.0 个月(HR=0.71,95%CI 0.3-1.7),未达统计学显著。

要点

  • ER+/HER2- 转移性乳腺癌按 18F-FES SUV 分层,内分泌反应性呈异质性。
  • SUV<2 者随机接受内分泌治疗 vs 化疗,中位 PFS 12.4 vs 23.0 个月(HR=0.71,95%CI 0.3-1.7)。
  • SUV≥2 者接受内分泌治疗中位 PFS 18.0 个月,中位 OS 未达到。

核心结论

  • ET-FES 试验表明 ER+/HER2- 转移性乳腺癌为异质性人群,基于 18F-FES CT/PET SUV 可区分不同水平的内分泌反应性。

研究设计与样本

  • ET-FES 先导研究: eligible 患者基线接受 18F-FES PET/CT,SUV≥2 者接受单药内分泌治疗直至疾病进展,SUV<2 者随机分配至单药内分泌治疗(A 组)或化疗(B 组)。
  • 共入组 147 例患者,其中 117 例 SUV≥2 接受内分泌治疗,30 例 SUV<2 随机分配至内分泌治疗或化疗。
  • 主要目标为比较 SUV<2 患者中一线内分泌治疗与化疗的活性。

主要发现

  • 中位随访 62.4 个月,104 例(73.2%)出现疾病进展,53 例(37.3%)死亡。
  • SUV<2 随机至 A 组(内分泌治疗)的中位 PFS 为 12.4 个月(95%CI 3.1-59.6 个月),B 组(化疗)为 23.0 个月(95%CI 7.7-30.0 个月),HR=0.71(95%CI 0.3-1.7 个月)。
  • SUV≥2 接受内分泌治疗患者的中位 PFS 为 18.0 个月(95%CI 11.2-23.1 个月)。
  • SUV<2 随机至 A 组的中位 OS 为 28.2 个月(95%CI 14.2 个月-不可估计),B 组为 52.8 个月(95%CI 16.2 个月-不可估计);SUV≥2 者中位 OS 未达到。
  • 60 个月 OS 率:A 组 41.6%(95%CI 10.4%-71.1%),B 组 42.0%(95%CI 14.0%-68.2%),SUV≥2 者为 59.6%(95%CI 48.6%-69.0%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 18F-fluoroestradiol (FES) positron emission tomography (PET)/computed tomography (CT) is considered an accurate diagnostic tool to determine whole-body endocrine responsiveness. In the endocrine therapy (ET)-FES trial, we evaluated 18F-FES PET/CT as a predictive tool in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). PATIENTS AND METHODS: Eligible patients underwent an 18F-FES PET/CT at baseline. Patients with standardized uptake value (SUV) ≥ 2 received single-agent ET until progressive disease; patients with SUV < 2 were randomized to single-agent ET (arm A) or chemotherapy (ChT) (arm B). The primary objective was to compare the activity of first-line ET versus ChT in patients with 18F-FES SUV < 2. RESULTS: Overall, 147 patients were enrolled; 117 presented with 18F-FES SUV ≥ 2 and received ET; 30 patients with SUV < 2 were randomized to ET or ChT. After a median follow-up of 62.4 months, 104 patients (73.2%) had disease progression and 53 died (37.3%). Median progression-free survival (PFS) was 12.4 months [95% confidence interval (CI) 3.1-59.6 months] in patients with SUV < 2 randomized to arm A versus 23.0 months (95% CI 7.7-30.0 months) in arm B, [hazard (HR) = 0.71, 95% CI 0.3-1.7 months]; median PFS was 18.0 months (95% CI 11.2-23.1 months) in patients with SUV ≥ 2 treated with ET. Median overall survival (OS) was 28.2 months (95% CI 14.2 months-not estimable) in patients with SUV < 2 randomized to ET (arm A) versus 52.8 months (95% CI 16.2 months-not estimable) in arm B (ChT). Median OS was not reached in patients with SUV ≥ 2. 60-month OS rate was 41.6% (95% CI 10.4% to 71.1%) in arm A, 42.0% (95% CI 14.0% to 68.2%) in arm B, and 59.6% (95% CI 48.6% to 69.0%) in patients with SUV ≥ 2. In patients with SUV ≥ 2, 60-month OS rate was 72.6% if treated with aromatase inhibitors (AIs) versus 40.6% in case of fulvestrant or tamoxifen (P < 0.005). CONCLUSIONS: The ET-FES trial demonstrated that ER+/HER2- MBC patients are a heterogeneous population, with different levels of endocrine responsiveness based on 18F-FES CT/PET SUV.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Gennari A, Brain E, De Censi A, et al. Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET. Ann Oncol. 2024. PMID: 38423389. doi:10.1016/j.annonc.2024.02.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。